NeuroVive Pharmaceutical AB Interim report January – June 2017
Strategic in-licensing broadens the project portfolio
Press releases
NeuroVive Pharmaceutical – Interim report January-June 2016
Business operations
NeuroVive share upgraded to OTC Markets Group – OTCQX Best Market in the US
NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, has announced that the company's share has been upgraded to trading on the OTC Market Group's best market, OTCQX in the US. The ...
NeuroVive: Interim Report 1 Jan. 2016 to 31 Mar. 2016
Full speed ahead First Quarter (1 Jan. 2016 – 31 Mar. 2016)Net revenues were SEK 0 (0) and other operating income was SEK 46,000 (49,000).Loss before tax was SEK 10,916,000 […]
Updated timeline for conversion of NeuroVive’s BTUs into shares and warrants
NeuroVive Pharmaceutical AB (publ) announces that registration of the preferential rights issue totaling SEK 94.4 m has now been completed, and provides an updated timeline for the conversion of Neuro ...
NeuroVive preferential rights issue fully subscribed
NeuroVive Pharmaceutical AB (publ) has completed the preferential rights issue of units, comprising shares and warrants, authorized by the Extraordinary General Meeting on 31 March 2016. The preferent ...
NeuroVive Pharmaceutical AB (publ): Report from AGM
NeuroVive Pharmaceutical AB (publ) held its Annual General Meeting (AGM) yesterday, 28 April 2016. A summary of the resolutions follows. All resolutions were passed with the required majority.
NeuroVive’s R&D Team to Present Research Progress at Mitochondrial Medicine Conference
NeuroVive Pharmaceutical AB (publ), the pioneers in mitochondrial medicine, will present important research findings together with researchers at Lund University in three scientific poster presentatio ...
NeuroVive insiders and employees intend to subscribe for a minimum of 5.4 million SEK
NeuroVive Pharmaceutical AB (publ) announces that board members, other insiders and employees intend to subscribe for a minimum of 129 000 units, equivalent to at least SEK 5.4 million, in the company ...
NeuroVive starts preclinical TBI program in collaboration with PENN
NeuroVive Pharmaceutical AB (publ), the pioneers in mitochondrial medicine, announces the start of the first study in the preclinical program in traumatic brain injury (TBI) which is being done in col ...
NeuroVive: large shareholder to participate in the rights issue
NeuroVive Pharmaceutical AB (publ) announces that Baulos Capital Belgium SA, one of the largest shareholders, intends to participate in the upcoming rights issue.
NeuroVive publishes prospectus and announces new publication date of the Q1 interim report
On 28 February 2016, the Board of Directors of NeuroVive Pharmaceutical AB (publ) ("NeuroVive") decided to carry out a new issue of shares and warrants (units) with preferential rights for the company ...